Comparative Pharmacology
Head-to-head clinical analysis: AVENTYL versus IMIPRAMINE PAMOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVENTYL versus IMIPRAMINE PAMOATE.
AVENTYL vs IMIPRAMINE PAMOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
Imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
150-300 mg orally once daily at bedtime for depression; 75-150 mg/day for panic disorder.
None Documented
None Documented
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
11-25 hours (mean 19 h); extended in elderly (up to 30 h) and hepatic impairment; clinical context: steady-state reached in 7-14 days
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
Primarily renal (70% as metabolites, <5% unchanged); 20-30% fecal via biliary excretion
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant